These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 34105505)

  • 41. Convalescent Blood: Current Perspective on the Efficacy of a Legacy Approach in COVID-19 Treatment.
    Sheervalilou R; Shirvaliloo M; Sargazi S; Bahari S; Saravani R; Shahraki J; Shirvalilou S; Shahraki O; Nazarlou Z; Shams Z; Ghaznavi H
    Blood Purif; 2022; 51(1):1-14. PubMed ID: 33789273
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High-Dose Convalescent Plasma for Treatment of Severe COVID-19 (response).
    De Santis GC; Calado RT
    Emerg Infect Dis; 2022 May; 28(5):1083-1084. PubMed ID: 35447061
    [No Abstract]   [Full Text] [Related]  

  • 43. Convalescent plasma for COVID-19 complicated by ARDS due to TRALI.
    Wang KY; Shah P; Pierce M
    BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33509890
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Patients with Prolonged Positivity of SARS-CoV-2 RNA Benefit from Convalescent Plasma Therapy: A Retrospective Study.
    Wu Y; Hong K; Ruan L; Yang X; Zhang J; Xu J; Pan S; Ren L; Chen L; Huang C; Shang Y
    Virol Sin; 2020 Dec; 35(6):768-775. PubMed ID: 32865701
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters.
    Takamatsu Y; Imai M; Maeda K; Nakajima N; Higashi-Kuwata N; Iwatsuki-Horimoto K; Ito M; Kiso M; Maemura T; Takeda Y; Omata K; Suzuki T; Kawaoka Y; Mitsuya H
    J Virol; 2022 Feb; 96(4):e0155121. PubMed ID: 34818068
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A review: Epidemiology, pathogenesis and prospect in developing vaccines for novel Coronavirus (COVID-19).
    Gupta P
    Indian J Tuberc; 2021 Jan; 68(1):92-98. PubMed ID: 33641858
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Plasma from donors convalescent from SARS-CoV-2 infection-A matter of priorities.
    Farrugia A
    Transfus Clin Biol; 2020 Aug; 27(3):167-168. PubMed ID: 32563550
    [No Abstract]   [Full Text] [Related]  

  • 48. Therapeutic plasma exchange followed by convalescent plasma transfusion in critical COVID-19-An exploratory study.
    Jaiswal V; Nasa P; Raouf M; Gupta M; Dewedar H; Mohammad H; Al Rais Z; Ali Baqer M; Alsabbah A; Ibrahim Y; Salem M; Shammass D; Marashi M
    Int J Infect Dis; 2021 Jan; 102():332-334. PubMed ID: 33157287
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of immunocompromised COVID-19 patients with convalescent plasma.
    Fung M; Nambiar A; Pandey S; Aldrich JM; Teraoka J; Freise C; Roberts J; Chandran S; Hays SR; Bainbridge E; DeVoe C; Roque Gardner A; Yokoe D; Henrich TJ; Babik JM; Chin-Hong P
    Transpl Infect Dis; 2021 Apr; 23(2):e13477. PubMed ID: 32989856
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High-throughput detection of antibodies targeting the SARS-CoV-2 Spike in longitudinal convalescent plasma samples.
    Anand SP; Prévost J; Richard J; Perreault J; Tremblay T; Drouin M; Fournier MJ; Lewin A; Bazin R; Finzi A
    Transfusion; 2021 May; 61(5):1377-1382. PubMed ID: 33604922
    [TBL] [Abstract][Full Text] [Related]  

  • 51. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.
    Volk A; Covini-Souris C; Kuehnel D; De Mey C; Römisch J; Schmidt T
    BioDrugs; 2022 Jan; 36(1):41-53. PubMed ID: 34843105
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Convalescent plasma therapy for coronavirus infection: experience from MERS and application in COVID-19.
    Al-Tawfiq JA; Arabi Y
    Hum Vaccin Immunother; 2020 Dec; 16(12):2973-2979. PubMed ID: 32881641
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for COVID-19.
    Jin C; Yu B; Zhang J; Wu H; Zhou X; Yao H; Liu F; Lu X; Cheng L; Jiang M; Wu N
    BMC Infect Dis; 2021 Apr; 21(1):357. PubMed ID: 33863281
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Convalescent plasma treatment of critically ill intensive care COVID-19 patients.
    Lindemann M; Lenz V; Knop D; Klump H; Alt M; Aufderhorst UW; Schipper L; Schwarzkopf S; Meller L; Steckel N; Koldehoff M; Heinold A; Heinemann FM; Fischer J; Hutschenreuter G; Knabbe C; Dolff S; Brenner T; Dittmer U; Witzke O; Herbstreit F; Horn PA; Krawczyk A
    Transfusion; 2021 May; 61(5):1394-1403. PubMed ID: 33784412
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The presence of anti-leucocyte antibodies in the plasma of convalescent women after SARS-CoV-2 infection as a reason for disqualification for plasma therapy - analysis based on a literature review.
    Wendlocha D; Janusz A; Janusz J; Królewska-Daszczyńska P; Englisz A; Smycz-Kubańska M; Mielczarek-Palacz A
    Pol Merkur Lekarski; 2021 Jun; 49(291):227-230. PubMed ID: 34218245
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of convalescent serum reduces severity of COVID-19 in nonhuman primates.
    Cross RW; Prasad AN; Borisevich V; Woolsey C; Agans KN; Deer DJ; Dobias NS; Geisbert JB; Fenton KA; Geisbert TW
    Cell Rep; 2021 Mar; 34(10):108837. PubMed ID: 33662255
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical characteristics and plasma antibody titer of patients with COVID-19 in Zhejiang, China.
    Xiang WL; Cheng JJ; Wu LP; Chen BY; Li WX; Qiu DY; Zhang W; Ge FH; Chen D; Wang Z
    J Zhejiang Univ Sci B; 2020 Dec.; 21(12):955-960. PubMed ID: 33843161
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial.
    Madariaga MLL; Guthmiller JJ; Schrantz S; Jansen MO; Christensen C; Kumar M; Prochaska M; Wool G; Durkin-Celauro A; Oh WH; Trockman L; Vigneswaran J; Keskey R; Shaw DG; Dugan H; Zheng NY; Cobb M; Utset H; Wang J; Stovicek O; Bethel C; Matushek S; Giurcanu M; Beavis KG; di Sabato D; Meltzer D; Ferguson MK; Kress JP; Shanmugarajah K; Matthews JB; Fung JF; Wilson PC; Alverdy JC; Donington JS
    J Intern Med; 2021 Apr; 289(4):559-573. PubMed ID: 33034095
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interferon-α2 Auto-antibodies in Convalescent Plasma Therapy for COVID-19.
    Raadsen MP; Gharbharan A; Jordans CCE; Mykytyn AZ; Lamers MM; van den Doel PB; Endeman H; van den Akker JPC; GeurtsvanKessel CH; Koopmans MPG; Rokx C; Goeijenbier M; van Gorp ECM; Rijnders BJA; Haagmans BL
    J Clin Immunol; 2022 Feb; 42(2):232-239. PubMed ID: 34767118
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Convalescent Plasma for Preventing Critical Illness in COVID-19: a Phase 2 Trial and Immune Profile.
    Sturek JM; Thomas TA; Gorham JD; Sheppard CA; Raymond AH; Petros De Guex K; Harrington WB; Barros AJ; Madden GR; Alkabab YM; Lu DY; Liu Q; Poulter MD; Mathers AJ; Thakur A; Schalk DL; Kubicka EM; Lum LG; Heysell SK
    Microbiol Spectr; 2022 Feb; 10(1):e0256021. PubMed ID: 35196802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.